The Multicenter, Phase II Prospective Study of Paclitaxel Plus Capecitabine as First-Line Chemotherapy in Advanced Gastric Carcinoma

BACKGROUND. The efficacy and toxicity of paclitaxel plus capecitabine (PX) as first-line treatment in advanced gastric cancer (AGC) was evaluated. METHODS. Patients with previously untreated AGC were included. PX was given every 3 weeks until a maximum of six cycles or progression. Capecitabine mono...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Gong, Jifang, Hu, Bing, Zhang, Xiaotian, Zhang, Fengchun, Zhang, Jun, Xu, Nong, Fan, Qingxia, Bai, Yuxian, Jiao, Shunchang, Wang, Jinwan, Bai, Chunmei, Zheng, Leizhen, Shi, Yingqiang, Liu, Yunpeng, Liang, Jun, Hu, Guoqing, Cheng, Ying, Xu, Ruihua, Bai, Yu, Shen, Lin
Formato: Artigo
Idioma:Inglês
Publicado: AlphaMed Press 2014
Assuntos:
Clinical Trial Results
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC3926790/
https://ncbi.nlm.nih.gov/pubmed/24457378
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2013-0137
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares